Mobile website
Effects of Repeated Treatment by Anticancer Drugs on Expression of erbB-2, p53 and MDR1 in Human Lung Cancer Cell Line
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To explore the variation of the proteins of erbB-2, p53 and MDR1 in repeated treatment by anticancer drugs and the effects on biotherapy. Methods:The human lung cancer cell line (LPET-a-1) was repeatedly treated by anticancer drugs—doxorubicin, etoposide, cisplatin and combination of the three drugs, and every drug was given in two concentrations. erbB-2, p53 and MDR1 were tested by flow cytometry. The percentage of cells expressing these proteins and the mean quantity of them were acquired. We could calculate the number of cells expressing each protein, the mean quantity of each protein and the total one after each treatment by different drugs in different concentration. Results:The levels of every protein decreased along with the time of cell culture. In high-dose groups, almost every item of erbB-2 and MDR1 was downregulated along with the times of treatment. In low-dose groups, there was not a rule of the item's variation and some of them increased. There was not a rule of p53 variation, and the expression of it in drug groups was higher than that in control at the third drug treatment.Conclusion:After treated by anticancer drugs, especially in low-dose, the expressions of erbB-2, p53 and MDR1 increased at different level. These data suggested that the patients suffering from cancer should be given adequate biotherapy after chemotherapy in clinical practice.
Keywords:
Project Supported:
Clc Number:
